319 related articles for article (PubMed ID: 9951948)
1. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.
Cooper KL; McKiernan JM; Kaplan SA
Drugs; 1999 Jan; 57(1):9-17. PubMed ID: 9951948
[TBL] [Abstract][Full Text] [Related]
2. Benign prostatic hyperplasia. Practical treatment guidelines.
Tammela T
Drugs Aging; 1997 May; 10(5):349-66. PubMed ID: 9143856
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
4. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
Plosker GL; Goa KL
Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
[TBL] [Abstract][Full Text] [Related]
5. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
6. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
Chapple CR
Eur Urol; 1996; 29(2):129-44. PubMed ID: 8647139
[TBL] [Abstract][Full Text] [Related]
7. The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview.
Hieble JP; Ruffolo RR
Pharmacol Res; 1996 Mar; 33(3):145-60. PubMed ID: 8880886
[TBL] [Abstract][Full Text] [Related]
8. Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
Beduschi MC; Beduschi R; Oesterling JE
Urology; 1998 Jun; 51(6):861-72. PubMed ID: 9609620
[TBL] [Abstract][Full Text] [Related]
9. alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia.
Thiyagarajan M
Pharmacology; 2002 Jul; 65(3):119-28. PubMed ID: 12037374
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of tamsulosin, doxazosin, and terazosin in the treatment of benign prostatic hyperplasia.
Ohsfeldt RL; Kreder KJ; Klein RW; Chrischilles EA
J Manag Care Pharm; 2004; 10(5):412-22. PubMed ID: 15369424
[TBL] [Abstract][Full Text] [Related]
11. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Tarter TH; Vaughan ED
Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
[TBL] [Abstract][Full Text] [Related]
13. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
Wilde MI; Fitton A; McTavish D
Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
[TBL] [Abstract][Full Text] [Related]
14. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
15. The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.
Fonseca J; Martins da Silva C
Clin Drug Investig; 2015 Feb; 35 Suppl 1():7-18. PubMed ID: 25708606
[TBL] [Abstract][Full Text] [Related]
16. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
McKeage K; Plosker GL
Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
18. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options.
Sandhu JS; Vaughan ED
Drugs Aging; 2005; 22(11):901-12. PubMed ID: 16323969
[TBL] [Abstract][Full Text] [Related]
20. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F
BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
